Guidelines for donor selection have changed to expand the donor pool, considering potential donors affected by a neoplasm. Aim of this retrospective study is to look at the use of organs from donors with a current or history of neoplasm within the Italian Transplant Network. Data, collected and validated by Italian National Health Institute for the time interval 2006–2015, have been reviewed retrospectively by mean of multivariable pivot tables. Donors with neoplasia represented about 5% of all donors, resulting in about 4% of all transplants. Donors presented a benign neoplasm in 29.08% of cases, a malignancy with variable risk of transmission in 69.75% while in 1.34% the nature of neoplasm could not be assessed. Considering all procedures, rate of transmission of a malignancy was 0.03% (10 cases) of all 29858 transplants of the time interval. Notably, cases of transmission were not from donors of this pool, but from donors that, according to our protocols, had no elements of suspect at time of donation. As recipient safety is always the priority and as guidelines have set exclusion criteria for donors with some specific types of malignancy, these results show that use of this type of donors is safe and improve organ pool. Furthermore represent basis for improvement and standardization of donor assessment protocols suggesting that efforts in data collection systems, to produce complete and homogeneous data, are mandatory.
Transplantation Donor with malignancy Donor evaluation Risk assessment Neoplastic transmission
This is a preview of subscription content, log in to check access.
Supported by Internal Funding (MB, GZ and AD-FUR 2017).
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (authorization 1745CESC on behalf of MeTTOs group) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
White SL, Hirth R, Mahíllo B, Domínguez-Gil B, Delmonico FL, Noel L et al (2014) The global diffusion of organ transplantation: trends, drivers and policy implications. Bull World Health Organ 92(11):826–835CrossRefGoogle Scholar
Eccher A, Boschiero L, Fior F, Casartelli Liviero M, Zampicini L, Ghimenton C et al (2014) Donor kidneys with miliary papillary renal cell neoplasia: the role of the pathologist in determining suitability for transplantation. Ann Transplant 19:362–366CrossRefGoogle Scholar
Desai R, Collett D, Watson CJE, Johnson P, Evans T, Neuberger J (2014) Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg 101(7):768–774CrossRefGoogle Scholar
Kauffman HM, Cherikh WS, McBride M, Cheng Y, Hanto DW (2007) Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 84(2):272–274CrossRefGoogle Scholar
Birkeland SA, Storm HH (2002) Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 74(10):1409–1413CrossRefGoogle Scholar
Fiorentino M, DErrico A, Corti B, Casanova S, Ridolfi L, Venturoli N et al (2003) A multiorgan donor cancer screening protocol: the Italian Emilia-Romagna region experience. Transplantation 76(12):1695–1699CrossRefGoogle Scholar
Engels EA, Castenson D, Pfeiffer RM, Kahn A, Pawlish K, Goodman MT et al (2014) Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses. Am J Transplant 14(6):1376–1382CrossRefGoogle Scholar
Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G (2013 Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant 13(10):2645–2652CrossRefGoogle Scholar
Warrens AN, Birch R, Collett D, Daraktchiev M, Dark JH, Galea G et al (2012) Advising potential recipients on the use of organs from donors with primary central nervous system tumors. Transplantation 93:348–353CrossRefGoogle Scholar
Adler JT, Yeh H, Barbesino G, Lubitz CC (2017) Reassessing risks and benefits of living kidney donors with a history of thyroid cancer. Clin Transplant 31(11):e13114CrossRefGoogle Scholar
Eccher A, Cima L, Ciangherotti A, Montin U, Violi P, Carraro A et al (2017) Rapid screening for malignancy in organ donors. 15 years experience with the Verona “Alert” protocol and review of the literature. Clin Transplant 31(9):e13045CrossRefGoogle Scholar
Kauffman HM, McBride MA, Delmonico FL (2000 Dec) First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 70(12):1747–1751CrossRefGoogle Scholar
Pandanaboyana S, Longbotham D, Hostert L, Attia M, Baker R, Menon K et al (2016) Transplantation of liver and kidney from donors with malignancy at the time of donation: an experience from a single centre. Transpl Int 29(1):73–80CrossRefGoogle Scholar
Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J (2012) Cancer transmission from organ donors—unavoidable but low risk. Transplant J 94(12):1200–1207CrossRefGoogle Scholar
Watson CJE, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH et al (2010) How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK registry data. Am J Transplant 10(6):1437–1444CrossRefGoogle Scholar
Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG et al (2003) Donors with central nervous system malignancies: are they truly safe? Transplantation 76(2):340–343CrossRefGoogle Scholar
Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J et al (2010) Melanoma in solid organ transplant recipients. Am J Transplant 10(5):1297–1304CrossRefGoogle Scholar
Strauss DC, Thomas JM (2010) Transmission of donor melanoma by organ transplantation. Lancet Oncol 11(8):790–796CrossRefGoogle Scholar
Zhang S, Yuan J, Li W, Ye Q (2014) Organ transplantation from donors (cadaveric or living) with a history of malignancy: review of the literature. Transplant Rev (Orlando) 28(4):169–175CrossRefGoogle Scholar
Nalesnik MA, Woodle ES, Dimaio JM, Vasudev B, Teperman LW, Covington S et al (2011) Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 11(6):1140–1147CrossRefGoogle Scholar
Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM (2002) Transplant tumor registry: donor related malignancies. Transplantation 74(3):358–362CrossRefGoogle Scholar
Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW (2003) Tumors and transplantation: the 2003 third annual ASTS state-of-the-art winter symposium. Am J Transplant 3(12):1481–1487CrossRefGoogle Scholar
Benkö T, Hoyer DP, Saner FH, Treckmann JW, Paul A, Radunz S (2017) Liver transplantation from donors with a history of malignancy: a single-center experience. Transplant Direct 3(11):e224CrossRefGoogle Scholar
Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Teperman LW (2008) Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant 8(1):238–2344Google Scholar
Dziewanowski K, Drozd R, Parczewski M, Klinke M (2014) Multiorgan transplantation from a deceased donor with intravascular diffuse large B-cell lymphoma: transmission of the disease and results of treatment. Clin Transplant 28(10):1080–1083CrossRefGoogle Scholar
Frascà GM, D’Errico A, Malvi D, Porta C, Cosmai L, Santoni M et al (2016) Transplantation of kidneys with tumors. J Nephrol 29(2):163–168CrossRefGoogle Scholar
Geissler EK (2015) Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol 12(12):705–717CrossRefGoogle Scholar
Mazzucotelli V, Piselli P, Verdirosi D, Cimaglia C, Cancarini G, Serraino D et al. (2017) De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997–2012. J Nephrol 30(6):851–857CrossRefGoogle Scholar